Close Menu

Researchers at Massachusetts General Hospital have developed a microfluidics chip that captures rare cancer cells in numbers that are high enough to enable analysis for molecular markers, reports Technology Review's Emily Singer. The device could save patients the hassle and pain of tumor biopsies since a sufficient number of cells could be culled from the bloodstream, and doctors could pick better drugs for their patients by doing the molecular marker analysis, she adds.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.